Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Soft tissue sarcoma is a rare type of cancer that develops in soft tissues of the human body, such as fat, muscle, nerves, fibrous tissues, or deep skin tissues. About 40 percent of the cases occur in the legs, usually at or above the knee. Fifteen percent develop in the hands and arms, another 15 percent in the head and neck, and the remaining 30 percent in the shoulders, chest, abdomen, or hips. Moreover, it is not classified as a tumour but can be life-threatening if cancer spreads in the human body.
Increasing Prevalence of Different Types of Cancers
Growing occurrences of various types of cancer, which start in soft tissues such as tendons, fat, nerves, blood vessels, and others, are expected to propel the growth of the market. There is a rise in the number of cases of sarcoma, which is augmenting the growth of the market. According to cancer research UK, there are about 4,300 new soft tissue sarcoma cases in England every year, which is around 12 every day. The elderly population is more at risk as they can develop soft tissue sarcoma cancer. Around 40 in 100 soft tissue sarcomas (40%) are diagnosed in individuals aged 65 or above.Increasing Research & Development (R&D) Activities
There is a rise in the number of research activities on drugs and other therapies, which is likely to bolster the growth of the market. Researchers are focusing on second-line therapies for patients who relapse or are refractory, as there are no approved therapies for the same. Heavy funding by the government, as well as the private sector for R&D purposes, is facilitating the growth of the market.Rise in the Number of Clinical Trials
There is a large number of clinical studies which are going on for soft tissue sarcoma in the region, which is projected to bolster the growth of the market. There are a total of 578 clinical studies in Europe, out of which 242 studies are completed. For instance, in 2021, a clinical trial for the “NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms with Soft Tissue Sarcoma of the Extremity and Trunk Wall” was completed.Market Segmentation
Europe soft tissue sarcoma market is segmented into treatment, disease type, end user, company, and country. Based on treatment, the market is divided into targeted therapy, chemotherapy, anti-angiogenesis drug, and radiation therapy. Based on disease type, the market is categorized into local sarcoma, regional sarcoma, and metastatic sarcoma. Based on end users, the market is bifurcated into hospitals & clinics, ambulatory surgical centers, and others. In terms of countries, the market is categorized into Germany, France, United Kingdom, Italy, Spain, Netherlands, Belgium, Sweden, Poland, and Greece.Market Players
GlaxoSmithKline PLC, Eli Lilly Italia - S.p.A., Pfizer Deutschland GmbH., Bristol-Myers Squibb SARL, F. Hoffmann-La Roche AG, Teva Pharmaceuticals Europe BV, Celgene Europe Ltd, Zimmer GmbH, RTI UK Ltd, and Integra LifeSciences Services France SASU, are some of the leading companies in the market.Report Scope:
In this report, Europe soft tissue sarcoma market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:Europe Soft Tissue Sarcoma Market, By Treatment:
- Targeted Therapy
- Chemotherapy
- Anti-Angiogenesis Drug
- Radiation Therapy
Europe Soft Tissue Sarcoma Market, By Disease Type:
- Local Sarcoma
- Regional Sarcoma
- Metastatic Sarcoma
Europe Soft Tissue Sarcoma Market, By End User:
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
Europe Soft Tissue Sarcoma Market, By Country:
- France
- Germany
- United Kingdom
- Italy
- Spain
- Belgium
- Netherlands
- Sweden
- Poland
- Greece
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Europe soft tissue sarcoma market.Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- GlaxoSmithKline PLC
- Eli Lilly Italia - S.P.A.
- Pfizer Deutschland GmbH.
- Bristol-Myers Squibb SARL
- F. Hoffmann-La Roche AG
- Teva Pharmaceuticals Europe BV
- Celgene Europe Ltd
- Zimmer GmbH
- RTI UK Ltd
- Integra LifeSciences Services France SASU